Suchergebnisse - "Armuzzi, Alessandro"

PubPharm (427)

101

Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST) : an open-label, multicentre, randomised phase 3b trial

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Danese, S. | Vermeire, S. | D'Haens, G. | +99

CommentIn: Lancet Gastroenterol Hepatol. 2022 Apr;7(4):276-277. - PMID 35120657

102

Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents : A Case-Control Study

enthalten in: Biomedicines | 2022

von Papa, A. | Scaldaferri, F. | Covino, M. | +21

103

Hyperbaric oxygen therapy : More hope than hype for future treatment of perianal fistulizing Crohn's disease?

enthalten in: United European gastroenterology journal | 2022

von Armuzzi, A. | Pugliese, D.

CommentOn: United European Gastroenterol J. 2022 Mar;10(2):160-168. - PMID 35146959

104

Effectiveness of adalimumab for ulcerative colitis : A multicentre, retrospective study of clinical practice in Italy

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2022

von Vitello, A. | Grova, M. | Pugliese, D. | +25

105

COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases : Analysis of Determinants in a National Survey of the Italian IBD Patients' Association

enthalten in: Inflammatory bowel diseases | 2022

von Costantino, A. | Noviello, D. | Conforti, F. | +15

CommentIn: Inflamm Bowel Dis. 2021 Nov 18;:. - PMID 34792603

106

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA) : a randomised, double-blind, double-dummy, phase 3 study

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Danese, S. | Colombel, J. | Lukas, M. | +114

CommentIn: Lancet Gastroenterol Hepatol. 2022 Jan;7(1):2-4. - PMID 34798035

107

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY) : a phase 3, randomised, controlled trial

enthalten in: The lancet. Gastroenterology & hepatology | 2022

von Peyrin-Biroulet, L. | Hart, A. | Bossuyt, P. | +114

CommentIn: Lancet Gastroenterol Hepatol. 2022 Jan;7(1):2-4. - PMID 34798035

108

Effectiveness and safety of tofacitinib in ulcerative colitis : Done is better than perfect

enthalten in: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver | 2022

von Katsanos, K. | Armuzzi, A.

CommentOn: Dig Liver Dis. 2022 Feb;54(2):192-197. - PMID 34887214

109

Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases : a real-life multicenter, observational study in Italy

enthalten in: Expert opinion on biological therapy | 2022

von Tursi, A. | Mocci, G. | Allegretta, L. | +52

110

Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy : A Survey of the Italian Federation of Digestive Diseases - FISMAD

enthalten in: Helicobacter | 2022

von Zagari, R. | Romano, M. | Frazzoni, L. | +12